Vivodyne and the Post-Animal-Testing Economy: How AI + Human Tissue Is Reshaping Drug Discovery
For roughly seventy years, the standard route from a promising drug candidate to a first-in-human trial has run through mice. Now, at the intersection of new US regulatory permissions, breakthroughs in lab-grown human tissue, and…
Latest
Vivodyne and the Post-Animal-Testing Economy: How AI + Human Tissue Is Reshaping Drug Discovery
For roughly seventy years, the standard route from a promising drug candidate to a first-in-human trial has run…
RWE and KKR have closed about £12bn of investment for Vanguard West and East, 2.8 GW of offshore wind off Norfolk, backed by 35 banks and the National Wealth Fund. The deal shows what kind of energy project big capital will now fund, and on what terms.
CVS Health will separate its 9,000 drugstores from Aetna and Caremark by 2028, walking away from the idea that one company should own the insurer, the benefit manager and the pharmacy counter. Investors were not impressed, and employers have new questions to ask.
Microsoft is lobbying the White House to drop a planned ban on Chinese optical transceivers, the small fibre parts that carry data between AI chips. The fight shows how far tech security rules have travelled into the plumbing of the cloud, and who pays when they arrive.
Swiss fertility specialist Ferring has agreed to buy New York start-up Gameto for up to $1.38 billion, betting on a technology that could cut IVF stimulation from two weeks to three days. The deal shows how fast fertility care is moving from niche to mainstream.
GSK beat expectations on revenue and profit in the third quarter, yet its shares fell as much as 7% because vaccine sales went backwards. It is a sharp lesson in how markets judge a company by its weakest engine, not its average.
Eli Lilly’s next obesity drug has more than doubled the weight loss of Novo Nordisk’s Ozempic in a head-to-head trial. For employers already struggling with the cost of GLP-1 cover, the next generation of these medicines is arriving faster than budgets can adjust.
Training a frontier model makes headlines, but running it is where the money now goes. As AI moves from chatbots to agents that work all day, the cost of inference is deciding which providers make a profit, which chips win, and what enterprises should negotiate before they sign.
The Clinician Shortage: How AI Scribes and Automation Are Rewriting Healthcare’s Labour Economics
Health systems from Ohio to Oxford cannot hire enough doctors and nurses, and the ones they have are burning out under a mountain of paperwork. AI scribes and workflow automation are spreading faster than almost any technology in medical history. The early evidence is encouraging, but the real prize is a rethink of how clinical time is spent.
Subscribe to Updates
Get the latest updates from BusinessIQx delivered to your inbox.